Valentis Licenses Geneswitch Technology To Wyeth-Ayers

Valentis, Inc. has granted a non-exclusive license of the Company’s GeneSwitch gene regulation technology to Wyeth-Ayerst Laboratories.

The GeneSwitch system allows researchers to control the level and duration of selected genes in transgenic animals and cell cultures, aiding in the identification and characterization of a gene’s function.

Valentis is currently developing the GeneSwitch system as a component of a regulated erythropoietin gene medicine that it expects to take into human clinical testing.

The non-exclusive license is for research purposes only and consists of an up-front payment and annual maintenance fees.

No financial terms were disclosed.

Valentis maintains all rights to clinical gene therapy applications of the GeneSwitch technology.

“GeneSwitch technology will enable and enhance our efforts to mine the human genome for novel drug discovery targets,” states Dr. Charles W. Richard, Assistant Vice President of Genomics for Wyeth- Ayerst Research, the research unit of Wyeth-Ayerst.

“In deciding to license the GeneSwitch technology to pharmaceutical companies, Valentis has identified another business opportunity for its broad technology portfolio,” stated Michael P. Fons, Valentis’ Director of Business Development.

“The GeneSwitch system was initially made available to the academic research community through a license to Invitrogen. The license to Wyeth Ayerst represents the first commercial license of this technology to a major pharmaceutical company. We expect to conclude a number of similar licenses over the next year.”

Valentis, Inc. is a leader in the field of biopharmaceutical delivery.

The Company develops a broad array of products, proprietary technologies and intellectual property and applies its preclinical and early clinical development expertise to create novel therapeutics and improved versions of existing marketed biopharmaceuticals.

Buying Dragon Pharmaceuticals of Top Quality

Turanabol

Synthetic Anabolic Steroidal Agent
Main Chemical Name: 4-Chlorodehydromethyltestosterone
Branded by: Dragon Pharma Labs
Pack: 1 X 100 tablets (10 mg/pill)

TriTren 150 - Cheap Price

Administration: Injection
Prime Chemical Name: Tri Trenbolone
Producer: Dragon Pharma Labs
Package: 20 x 10 mL vial (150 mg/mL)
Price: 20 x $65.00

Cypionat 250 - Cheap Price

Administration: Injection
Prime Chemical Name: Testosterone Cypionate
Made by: Dragon Pharma LLC
Unit: 20 x 10 mL vial (250 mg/mL)
Price: 20 x $30.00

Oxymetholon - Bulk Price

Administration: Oral
Basal Substance: Oxymetholone
Manufacturer: Dragon Pharma
Amount: 10 x 100 pastilles (50 mg/tablet)
Price: 10 x $65.00

Propionat 100 - Bulk Price

Administration: Injection
Prime Substance: Testosterone Propionate
Branded by: Dragon Pharma Labs
Amount: 10 x 10 mL vial (100 mg/mL)
Price: 10 x $30.00

Deca 300 - Cheap Price

Administration: Injection
Primary Constituent: Nandrolone Decanoate
Producer: Dragon Pharma
Unit: 20 x 10 mL vial (300 mg/mL)
Price: 20 x $37.00

Deca 500

Injectable Anabolic Steroid
Prime Ingredient: Nandrolone Decanoate
Branded by: Dragon Pharma
Unit: 1 X 10 ml (500 mg/ml)

NPP 150 - Bulk Price

Administration: Injection
Primary Constituent: Nandrolone Phenylpropionate
Produced by: Dragon Pharma LLC
Package: 10 x 10 mL vial (150 mg/mL)
Price: 10 x $30.00

NPP 150

Injectable Steroid for Muscle Growth
Prime Ingredient: Nandrolone Phenylpropionate
Branded by: Dragon Pharma LLC
10 mL Sterile Multi-dose Vial (150 mg/mL)

Clomid

Prime Ingredient: Clomiphene Citrate
Branded by: Dragon Pharmaceuticals
Amount: 100 pastilles (50 mg/tab)

EQ 500

Injectable Steroid for Muscle Growth
Principal Chemical Name: Boldenone Undecylenate
Made by: Dragon Pharmaceuticals
10 mL Sterile Multi-dose Vial (500 mg/mL)

Suspension 100

Injectable Steroid for Muscle Growth
Primary Chemical Name: Testosterone Suspension
Made by: Dragon Pharma
10 mL Sterile Multi-dose Vial (100 mg/mL)